Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
Business Wire India NTX-001 continues to be generally safe and well tolerated, with no additional adverse effects NTX-001 demonstrated a clinically and statistically significant improvement in function at 24 weeks.…